27% of Saudis in ‘Bombshell’ Study Experienced Heart Issues After mRNA COVID Shots

9.45% required medical care for more than 12 months

The Saudi Arabian study, published in the medical journal Cureus, employed a cross-sectional design and recruited 804 participants (379 men, 425 women, ages 18 and above) who had received at least one dose of an mRNA COVID-19 vaccine (Pfizer-BioNTech, Moderna or both — 58 took a different brand).

Nearly 40% took just one shot.

Participants completed a culturally adapted questionnaire covering demographic details, vaccination history, health conditions and perceptions related to the vaccines.

The onset of cardiac complications for the 27.11% of affected participants varied, with 14.55% occurring within one month of vaccination, 6.97% between one and three months, and others experiencing issues up to 12 months or more after receiving the vaccine.

For the 15.8% admitted to critical care units and 11.44% to general hospital wards, inpatient treatment lasted from less than one day to several weeks, with 8.33% spending between four and seven days in the hospital.

Treatment for cardiac complications was ongoing for many participants, with 9.45% receiving medical care for more than 12 months and 7.11% undergoing continuous treatment at the time of the survey.

Sixty-five percent of subjects reported being “neutral,” “somewhat not confident” or “not confident at all” on the safety of mRNA vaccines, while only about 20% said they believed their cardiac symptoms were “strongly related” or “somewhat related” to the vaccines.

The study also found high rates of pre-existing health conditions among the participants, including diabetes (48.26%), hypertension (56.72%), obesity (39.15%) and sedentary lifestyle-related issues (22.14%).

These comorbidities may have contributed to the increased risk of cardiac complications following mRNA vaccination, according to the study authors…